Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday
by Jessica Moore · The Cerbat GemZoetis (NYSE:ZTS – Get Free Report) is expected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $1.61 per share and revenue of $2.3030 billion for the quarter. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the company posted $1.40 earnings per share. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. On average, analysts expect Zoetis to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Zoetis Trading Down 1.2%
Shares of ZTS stock opened at $112.81 on Tuesday. Zoetis has a 12-month low of $112.10 and a 12-month high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm’s 50 day moving average is $119.93 and its 200 day moving average is $124.53. The stock has a market capitalization of $47.45 billion, a P/E ratio of 18.74, a P/E/G ratio of 1.76 and a beta of 0.87.
Zoetis Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. State Street Corp lifted its stake in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares in the last quarter. Amundi lifted its stake in shares of Zoetis by 51.2% during the 4th quarter. Amundi now owns 4,001,317 shares of the company’s stock valued at $503,445,000 after buying an additional 1,354,581 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Zoetis by 4.6% during the 3rd quarter. Invesco Ltd. now owns 3,371,032 shares of the company’s stock valued at $493,249,000 after buying an additional 147,271 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Zoetis by 1.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,834,486 shares of the company’s stock valued at $356,649,000 after buying an additional 41,639 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its stake in shares of Zoetis by 85.9% during the 2nd quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after buying an additional 1,191,840 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Analyst Upgrades and Downgrades
ZTS has been the topic of several research reports. Citigroup began coverage on shares of Zoetis in a report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. UBS Group dropped their price target on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $151.75.
Check Out Our Latest Stock Analysis on ZTS
About Zoetis
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.